INTRODUCTION: Previous reports have shown a high frequency of hypocalcaemia and flu-like symptoms following an initial first zoledronic acid dose of 0.02-0.025 mg/kg in children. METHODS: We systematically evaluated the mineral status and symptomatology of 63 children with a variety of bone disorders treated with an initial zoledronic acid dose of 0.0125 mg/kg. The Mann-Whitney U test, chi-squared test and Fisher's exact test were used as appropriate. RESULTS: 0.0125 mg/kg zoledronic acid reduced the incidence and intensity of hypocalcaemia but not the incidence of the flu-like symptoms compared to higher doses. Within the low dose cohort, flu-like symptoms were associated with an acute inflammatory response. Children who became hypocalcaemic received a higher dose in relation to their body mass index and body surface area. CONCLUSION: Reducing the initial zoledronic acid dose in children decreased the incidence of hypocalcaemia and thus improved safety. Dosing on the basis of body mass index or body surface area instead of body weight may further reduce the incidence of hypocalcaemia.
INTRODUCTION: Previous reports have shown a high frequency of hypocalcaemia and flu-like symptoms following an initial first zoledronic acid dose of 0.02-0.025 mg/kg in children. METHODS: We systematically evaluated the mineral status and symptomatology of 63 children with a variety of bone disorders treated with an initial zoledronic acid dose of 0.0125 mg/kg. The Mann-Whitney U test, chi-squared test and Fisher's exact test were used as appropriate. RESULTS: 0.0125 mg/kg zoledronic acid reduced the incidence and intensity of hypocalcaemia but not the incidence of the flu-like symptoms compared to higher doses. Within the low dose cohort, flu-like symptoms were associated with an acute inflammatory response. Children who became hypocalcaemic received a higher dose in relation to their body mass index and body surface area. CONCLUSION: Reducing the initial zoledronic acid dose in children decreased the incidence of hypocalcaemia and thus improved safety. Dosing on the basis of body mass index or body surface area instead of body weight may further reduce the incidence of hypocalcaemia.
Authors: Leslie B Gordon; Monica E Kleinman; Joe Massaro; Ralph B D'Agostino; Heather Shappell; Marie Gerhard-Herman; Leslie B Smoot; Catherine M Gordon; Robert H Cleveland; Ara Nazarian; Brian D Snyder; Nicole J Ullrich; V Michelle Silvera; Marilyn G Liang; Nicolle Quinn; David T Miller; Susanna Y Huh; Anne A Dowton; Kelly Littlefield; Maya M Greer; Mark W Kieran Journal: Circulation Date: 2016-07-12 Impact factor: 29.690
Authors: Leslie B Gordon; Joe Massaro; Ralph B D'Agostino; Susan E Campbell; Joan Brazier; W Ted Brown; Monica E Kleinman; Mark W Kieran Journal: Circulation Date: 2014-05-02 Impact factor: 29.690